NR1H4 and metabolic dysfunction-associated steatohepatitis: MLGZG may serve as a novel mechanism for the treatment of NASH, as decreasing bile acid (BA) and farnesoid X receptor (FXR) signaling may yield metabolic benefits [8, 14–19].